ASH 2024: Daratumumab cuts risk of progression by half in smouldering multiple myeloma
Patients at high risk for developing multiple myeloma who received the drug daratumumab for up…
Browsing: ASH
ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for the Blenrep (belantamab mandolin) combination versus the…
ASH 2024: Combination of two oral agents improves progression-free survival in previously untreated chronic lymphocytic leukaemia
Among patients with previously untreated chronic lymphocytic leukemia (CLL), those who received a combination regimen…
ASH 2024: Ketogenic diet boosts CAR T-Cell function for better tumour control
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest…
ASH 2024: Resistance training can reduce fatigue, pain in multiple myeloma patients
Researchers from Roswell Park Comprehensive Cancer Center, USA, presented compelling findings showcasing the significant benefits…
ASH 2024: High-fibre diet may slow disease progression in multiple myeloma
New data suggest that a plant-based diet rich in fibre could help to improve the…
ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma
Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel…
ASH 2024: Combining BCL-2 and BTK inhibitors shows promise in CLL
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus…
ASH 2024: Multi-centre study shows education level and income impact access to stem cell transplantation for acute myeloid leukaemia patients
Patients with acute myeloid leukaemia who have lower education levels and lower income are less…
ASH 2024: High response rate, manageable adverse effects seen with epcoritamab in pretreated R/R CLL
In early results from a non-randomised study, the biologic agent epcoritamab, which leverages patients’ immune…